These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 21738816)
1. The proliferation markers Ki-67/MIB-1, phosphohistone H3, and survivin may contribute in the identification of aggressive ovarian carcinomas. Aune G; Stunes AK; Tingulstad S; Salvesen O; Syversen U; Torp SH Int J Clin Exp Pathol; 2011 Jun; 4(5):444-53. PubMed ID: 21738816 [TBL] [Abstract][Full Text] [Related]
2. Mitosin and pHH3 predict poorer survival in astrocytomas WHO grades II and III. Varughese RK; Lind-Landström T; Habberstad AH; Salvesen Ø; Haug CS; Sundstrøm S; Torp SH J Clin Pathol; 2016 Jan; 69(1):26-34. PubMed ID: 26188054 [TBL] [Abstract][Full Text] [Related]
3. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. Ladstein RG; Bachmann IM; Straume O; Akslen LA BMC Cancer; 2010 Apr; 10():140. PubMed ID: 20398247 [TBL] [Abstract][Full Text] [Related]
4. Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study. Heeran MC; Høgdall CK; Kjaer SK; Christensen L; Jensen A; Blaakaer J; Christensen IJ; Høgdall EV APMIS; 2013 Dec; 121(12):1177-86. PubMed ID: 23594232 [TBL] [Abstract][Full Text] [Related]
5. Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma. Nielsen PS; Riber-Hansen R; Jensen TO; Schmidt H; Steiniche T Mod Pathol; 2013 Mar; 26(3):404-13. PubMed ID: 23174936 [TBL] [Abstract][Full Text] [Related]
6. EPIGENETIC CHANGES - HISTONE 3 PHOSPHORYLATION - EPITHELIAL OVARIAN TUMORS. Munjishvili V; Barabadze E; Muzashvili T; Gachechiladze M; Burkadze G Georgian Med News; 2019 Sep; (294):128-131. PubMed ID: 31687964 [TBL] [Abstract][Full Text] [Related]
7. Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocytomas. Colman H; Giannini C; Huang L; Gonzalez J; Hess K; Bruner J; Fuller G; Langford L; Pelloski C; Aaron J; Burger P; Aldape K Am J Surg Pathol; 2006 May; 30(5):657-64. PubMed ID: 16699322 [TBL] [Abstract][Full Text] [Related]
8. Improving precise counting of mitotic cells in mantle cell lymphoma using phosphohistone H3 (PHH3) antibody. Medani H; Elshiekh M; Naresh KN J Clin Pathol; 2021 Oct; 74(10):646-649. PubMed ID: 32873701 [TBL] [Abstract][Full Text] [Related]
9. Scoring the percentage of Ki67 positive nuclei is superior to mitotic count and the mitosis marker phosphohistone H3 (PHH3) in terms of differentiating flat lesions of the bladder mucosa. Gunia S; Kakies C; Erbersdobler A; Koch S; May M J Clin Pathol; 2012 Aug; 65(8):715-20. PubMed ID: 22554964 [TBL] [Abstract][Full Text] [Related]
10. The Impact of Phosphohistone-H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic Neuroendocrine Tumors. Ozturk Sari S; Taskin OC; Gundogdu G; Yegen G; Onder S; Keskin M; Saglam S; Ozluk Y; Gulluoglu M; Mete O Endocr Pathol; 2016 Jun; 27(2):162-70. PubMed ID: 26936845 [TBL] [Abstract][Full Text] [Related]
11. Phosphohistone-H3 (PHH3) is prognostic relevant in Merkel cell carcinomas but Merkel cell polyomavirus is a more powerful prognostic factor than AJCC clinical stage, PHH3, Ki-67 or mitotic indices. Iwasaki T; Matsushita M; Nonaka D; Kato M; Nagata K; Murakami I; Hayashi K Pathol Int; 2015 Aug; 65(8):404-9. PubMed ID: 25982855 [TBL] [Abstract][Full Text] [Related]
12. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions. Nasr MR; El-Zammar O Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113 [TBL] [Abstract][Full Text] [Related]
13. Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas. Duregon E; Bertero L; Pittaro A; Soffietti R; Rudà R; Trevisan M; Papotti M; Ventura L; Senetta R; Cassoni P Oncotarget; 2016 Apr; 7(16):21190-8. PubMed ID: 27049832 [TBL] [Abstract][Full Text] [Related]
15. Phosphohistone-H3 Proliferation Index Is Superior to Mitotic Index and MIB-1 Expression as a Predictor of Recurrence in Human Meningiomas. Winther TL; Arnli MB; Salvesen Ø; Torp SH Am J Clin Pathol; 2016 Oct; 146(4):510-20. PubMed ID: 27686177 [TBL] [Abstract][Full Text] [Related]
16. Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas. Voss SM; Riley MP; Lokhandwala PM; Wang M; Yang Z Am J Surg Pathol; 2015 Jan; 39(1):13-24. PubMed ID: 25353284 [TBL] [Abstract][Full Text] [Related]
17. Nuclear survivin is associated with malignant potential in epithelial ovarian carcinoma. Qian X; Xi X; Li L Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):126-32. PubMed ID: 20724919 [TBL] [Abstract][Full Text] [Related]
18. Phospho-histone H3 (pHH3) immuno-reactivity as a prognostic marker in non-functioning pituitary adenomas. Hightower E; Cabanillas ME; Fuller GN; McCutcheon IE; Hess KR; Shah K; Waguespack SG; Corley LJ; Devin JK Pituitary; 2012 Dec; 15(4):556-61. PubMed ID: 22120760 [TBL] [Abstract][Full Text] [Related]
19. Immunostaining of phospho-histone H3 and Ki-67 improves reproducibility of recurrence risk assessment of gastrointestinal stromal tumors. Uguen A; Conq G; Doucet L; Talagas M; Costa S; De Braekeleer M; Marcorelles P Virchows Arch; 2015 Jul; 467(1):47-54. PubMed ID: 25823616 [TBL] [Abstract][Full Text] [Related]
20. The Utility of Phosphohistone H3 (PHH3) in Follicular Lymphoma Grading: A Comparative Study With Ki-67 and H&E Mitotic Count. Khieu ML; Broadwater DR; Aden JK; Coviello JM; Lynch DT; Hall JM Am J Clin Pathol; 2019 May; 151(6):542-550. PubMed ID: 30788495 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]